Ultrasound-responsive microcapsules for localized and on-demand drug delivery
This technology is a biphasic microcapsule-based platform that allows for the controlled release of therapeutics upon exposure to focused ultrasound.
Unmet Need: Localized drug delivery to reduce systemic toxicity
Systemic drug administration can result in multiple toxicities and off-target effects. Localized drug delivery systems can improve site therapeutic localization and reduce toxicity, but current methods are limited to passive release or bolus-release mechanisms. As such, these platforms are short-lived and require repeated therapeutic administration. There is a need for a platform capable of one-demand pulsatile release of therapeutics for longer-term drug delivery.
The Technology: Microcapsule platform for localized therapeutics delivery
This technology consists of biphasic microcapsules for the controlled release of therapeutics. The microcapsule has a dextran inner core that securely holds the therapeutic payload and an outer shell that prevents therapeutic release until stimulated by the focused ultrasound. Taken together, this platform can be used to deliver a variety of drug payloads and is stable for several months, enabling the minimally-invasive treatment of a broad range of diseases.
This technology has been validated in vitro.
Applications:
- Targeted chemotherapy
- Implantable biosensors
- Localized, on-demand, pulsatile drug-delivery
Advantages:
- Minimally invasive
- Targeted and repeated delivery with focused ultrasound triggering controlled release
- Longer-term treatment
- Adaptable for a variety of payloads with dextran core
- Reduces systemic toxicities
Lead Inventor:
Patent Information:
Patent Pending(WO/2023/107765)
Related Publications:
Tech Ventures Reference:
IR CU22072
Licensing Contact: Beth Kauderer